Loading...
Insights2021-01-12T11:48:07-05:00

The global impact of Precision Medicine Group.
As it happens.

Impact, observations, and insights on the evolving healthcare landscape.

Webinar: Pricing Strategies for Advanced Therapies

Cell & Gene Therapy, Events|

There is no doubt that the advanced therapies sector is growing at an exponential rate. According to a recently published 2021 Report by ARM (Alliance for Regenerative Medicine), the sector has raised $14.1B in financing in the first half of 2021 which is already 71% of what was raised in all of 2020. In addition, there are over 2,600 advance therapy clinical trials being conducted with 264 of those trails being Phase 3 trials and another 1,500 being Phase 2 trials.

(more…)

AMCP & Precision ADVANCE Corporate Training Program

Cell & Gene Therapy, Events|

Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies. These differences will impact how innovators develop evidence and manufacture and distribute products. Payers also need to adapt how they assess value, make coverage decisions, and manage reimbursement.

(more…)

Focus on Drug Prices Continues Amid Uncertainty Over Potential Changes

Cell & Gene Therapy, Thought Leadership|

High prescription drug prices continue to be of concern at the federal level. Despite proposed changes to drug pricing policy by the administration and HHS, industry experts question whether any significant changes will occur in the near future. Precision’s Ryan Cox and Erin Lopata weigh in on the factors contributing to the uncertainty about drug policy pricing changes.

(more…)

What Do Employers Need to Know About Specialty Drugs?

Cell & Gene Therapy, Thought Leadership|

Specialty drugs make up the bulk of the pharma pipeline. These drugs continue to come onto the market with higher and higher price tags, so employers should become more familiar with these therapies in order to properly manage them. Precision’s Erin Lopata and Jorge Font weigh in on the other considerations beyond cost that employers need to know for managing specialty drugs.

(more…)

Load More Posts